Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.1K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.5K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

429
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
429
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

250
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
250
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

29
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
29

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026
Same author

ChatGPT in the diagnosis and management of complex polyneuropathies: comparative analysis with neurologists using real-world cases.

NPJ digital medicine·2026
Same author

Heterogeneous Activated B Cell Compartments Arising Early and Transiently After SARS-CoV-2 Vaccination.

European journal of immunology·2026
Same author

Combining Activation-Induced Markers With PD-L1 Selectively Enhances Detection of Antigen-Specific T Cells in Virus-Infected Individuals.

Journal of immunology research·2026
Same author

Intravenous methylprednisolone as add-on induction therapy for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

SARS-CoV-2 mRNA Vaccination Leads to Transient Humoral and B Cell Bystander Responses in Adults.

European journal of immunology·2026

Related Experiment Video

Updated: Oct 7, 2025

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.2K

Immunoglobulin for multifocal motor neuropathy.

Stephen Keddie1, Filip Eftimov2, Leonard H van den Berg3

  • 1Faculty of Brain Sciences, Institute of Neurology, London, UK.

The Cochrane Database of Systematic Reviews
|January 11, 2022
PubMed
Summary

Intravenous immunoglobulin (IVIg) may improve muscle strength and disability in multifocal motor neuropathy (MMN). However, most patients experience worsening symptoms upon IVIg withdrawal, and subcutaneous immunoglobulin (SCIg) efficacy remains uncertain.

More Related Videos

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis
09:36

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis

Published on: June 23, 2022

3.6K
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

9.5K

Related Experiment Videos

Last Updated: Oct 7, 2025

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.2K
Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis
09:36

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis

Published on: June 23, 2022

3.6K
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

9.5K

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Multifocal motor neuropathy (MMN) is a rare, immune-mediated disorder causing progressive, asymmetric limb weakness without sensory loss.
  • Limited treatment options exist for MMN, with steroids and plasma exchange often ineffective.
  • Intravenous immunoglobulin (IVIg) has shown potential benefits in uncontrolled studies.

Purpose of the Study:

  • To assess the efficacy and safety of intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) for treating multifocal motor neuropathy (MMN).
  • To update previous Cochrane Review findings with new evidence on MMN treatments.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) and quasi-RCTs identified through comprehensive database searches.
  • Inclusion criteria focused on MMN patients receiving IVIg or SCIg, measuring disability, muscle strength, or conduction block.
  • Data extraction and risk of bias assessment were performed independently by two reviewers following Cochrane methodology.

Main Results:

  • IVIg demonstrated low-certainty evidence for improving muscle strength and disability in IVIg-naive MMN patients.
  • Moderate-certainty evidence indicates significant deterioration in disability and muscle strength upon IVIg withdrawal.
  • SCIg showed very uncertain efficacy compared to IVIg for maintenance treatment in MMN.

Conclusions:

  • IVIg may offer benefits for MMN symptoms, but its long-term efficacy and the potential for withdrawal require further investigation.
  • Evidence suggests that most IVIg responders relapse after treatment cessation.
  • SCIg presents a potential alternative, but more research is needed to confirm its efficacy as a maintenance therapy for MMN.